読み込み中
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
前日終値
$0.0715
$0.00 · 0.00%
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
52週レンジ
現在 $0.0715
過去の価格は調整または遅延している場合があります。
GoAI スコア
売り
バリュエーション
41
適正価値
センチメント
59
まちまち
リスク
63
高リスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
52週レンジ
現在 $0.0715
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | 7500 USD | 68.6万 USD | 28.4万 USD | 11万 USD |
| 粗利益 | — | 7500 USD | 68.6万 USD | 28.4万 USD | 11万 USD |
| 研究開発 | 483.6万 USD | 472.34万 USD | 364.32万 USD | 609.79万 USD | 538.01万 USD |
| 販売・一般管理 | 613.07万 USD | 626.93万 USD | 449.33万 USD | 363.97万 USD | 395.14万 USD |
| 営業費用 | 1096.67万 USD | 1099.26万 USD | 813.65万 USD | 973.76万 USD | 933.15万 USD |
| 受取利息 | 7.02万 USD | 12.26万 USD | 1577 USD | 4818 USD | 8759 USD |
| 支払利息 | 7587 USD | 1.22万 USD | 16.77万 USD | 25.19万 USD | 6.7万 USD |
| 減価償却費と償却費 | 45.31万 USD | 44.82万 USD | 42.55万 USD | 40.6万 USD | 8.48万 USD |
| 営業利益 | −1096.67万 USD | −1098.51万 USD | −745.05万 USD | −945.36万 USD | −922.15万 USD |
| 純利益 | −1095.54万 USD | −896.75万 USD | −1128.38万 USD | −1068.04万 USD | −893.97万 USD |
会社概要が更新されました 2026年10月17日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
